{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:58:23Z","timestamp":1776790703447,"version":"3.51.2"},"reference-count":25,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Allogeneic stem cell transplantation (allo-SCT) has seen limited use in treating multiple myeloma (MM), despite its potential to offer long-term survival or even cure through the graft-versus-myeloma effect. Its limited application is largely due to concerns over serious complications like infections and graft-versus-host disease (GVHD). The possibility of GVHD exacerbation when CAR-T cells are administered to patients previously treated with allo-SCT remains a topic of concern. Ciltacabtagene autoleucel (Cilta-cel) and idecabtagene vicleucel (Ide-cel) are CAR-T therapies that have been FDA-approved for relapsed\/refractory (R\/R) MM. A recent study using data from the CARTITUDE-1 trial has shown promising safety and efficacy of Cilta-Cel in patients with a prior history of allo-SCT. This report outlines our real-world experience with CAR-T treatment in such patients. The objective of this study is to assess the safety and effectiveness of CAR-T therapy in R\/R MM patients who have previously undergone allo-SCT. Methods: We conducted a retrospective analysis of adult patients (18\u201370 years old) with R\/R MM treated with CAR-T therapy as part of an institutional IRB-approved protocol. Data were collected on safety and efficacy outcomes from the institution\u2019s records. Adverse events (AEs) were evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were graded based on American Society for Transplantation and Cellular Therapy (ASTCT) criteria. Efficacy metrics included overall response rate (ORR) and progression-free survival (PFS), analyzed through the Kaplan\u2013Meier method, with PFS defined as the time from CAR-T initiation to disease progression or death. Results: Of the 56 patients treated with CAR-T therapy, 8 (14.3%) had previously undergone allo-SCT. These patients had a median of seven prior therapy lines (LOTs), compared to five LOTs in the non-allo-SCT group (p = 0.04). CAR-T infusion occurred a median of 98.8 months after allo-SCT, with a range from 57.9 months to 178.5 months. CRS occurred in 87.5% of the allo-SCT group versus 77.1% in the non-allo-SCT group (p = 0.48). One patient in the allo-SCT group developed hemophagocytic lymphohistiocytosis (HLH), requiring anakinra. At a median follow-up of 4.8 months, the ORR was 87.5% in the allo-SCT group versus 75% in the non-allo-SCT group (p = 0.4). Median PFS had not been reached for the allo-SCT group at the time of analysis compared to 11.9 months in the non-allo-SCT group (p = 0.5). No treatment-related mortality or acute GVHD was noted in the allo-SCT cohort. Conclusions: The study suggests that prior allo-SCT does not adversely affect the safety or efficacy of CAR-T therapy in patients with R\/R MM. These findings highlight the need for further investigations with larger patient samples and longer follow-up to better understand the interaction between allo-SCT and CAR-T therapy.<\/jats:p>","DOI":"10.3390\/jcm13206207","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T06:46:52Z","timestamp":1729234012000},"page":"6207","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of Allogeneic Stem Cell Transplant on Safety and Outcomes of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Patients with Multiple Myeloma (MM)"],"prefix":"10.3390","volume":"13","author":[{"given":"Ayrton","family":"Bangolo","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behzad","family":"Amoozgar","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4771-4970","authenticated-orcid":false,"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6794-6461","authenticated-orcid":false,"given":"Vignesh K.","family":"Nagesh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imranjot","family":"Sekhon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simcha","family":"Weissman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Vesole","sequence":"additional","affiliation":[{"name":"Division of Myeloma, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Phull","sequence":"additional","affiliation":[{"name":"Division of Myeloma, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Donato","sequence":"additional","affiliation":[{"name":"Division of Bone Marrow Transplant and Cellular Therapy, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noa","family":"Biran","sequence":"additional","affiliation":[{"name":"Division of Myeloma, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Siegel","sequence":"additional","affiliation":[{"name":"Division of Myeloma, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harsh","family":"Parmar","sequence":"additional","affiliation":[{"name":"Division of Myeloma, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.clml.2023.08.012","article-title":"Ciltacabtagene Autoleucel in Patients with Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study","volume":"23","author":"Htut","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of Chronic Graft-Versus-Host Disease and Therapeutic Targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/hematology.2020000111","article-title":"Future of CAR T cells in multiple myeloma","volume":"2020","author":"Wudhikarn","year":"2020","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_7","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1146\/annurev-immunol-102119-073227","article-title":"Current Concepts and Advances in Graft-Versus-Host Disease Immunology","volume":"39","author":"Hill","year":"2021","journal-title":"Annu. Rev. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: Recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S272","DOI":"10.1016\/j.htct.2021.10.460","article-title":"Updated results from the cartitude-1 study of ciltacabtagene autoleucel, a b-cell maturation antigen\u2013directed chimeric antigen receptor t cell therapy, in relapsed\/refractory multiple myeloma","volume":"43","author":"Usmani","year":"2021","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1200\/JCO.2021.39.15_suppl.8005","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed\/refractory multiple myeloma (R\/R MM): Updated results from CARTITUDE-1","volume":"39","author":"Usmani","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Chekol Abebe, E., Yibeltal Shiferaw, M., Tadele Admasu, F., and Asmamaw Dejenie, T. (2022). Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.991092"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s12185-023-03538-6","article-title":"Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma","volume":"117","author":"Minakata","year":"2023","journal-title":"Int. J. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13045-019-0758-x","article-title":"Target selection for CAR-T therapy","volume":"12","author":"Wei","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Zhang, X., Zhu, L., Zhang, H., Chen, S., and Xiao, Y. (2022). CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.927153"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.3324\/haematol.2022.282316","article-title":"Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience","volume":"108","author":"Sun","year":"2023","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-018-0568-6","article-title":"Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: Lessons learned and strategies for moving forward","volume":"11","author":"Li","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Benmebarek, M.R., Karches, C.H., Cadilha, B.L., Lesch, S., Endres, S., and Kobold, S. (2019). Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061283"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2991\/chi.k.201108.001","article-title":"CART Cell Toxicities: New Insight into Mechanisms and Management","volume":"2","author":"Zahid","year":"2020","journal-title":"Clin. Hematol. Int."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Fischer, J.W., and Bhattarai, N. (2021). CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.693016"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Greil, C., Engelhardt, M., Finke, J., and W\u00e4sch, R. (2021). Allogeneic Stem Cell Transplantation in Multiple Myeloma. Cancers, 14.","DOI":"10.3390\/cancers14010055"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41408-023-00900-z","article-title":"Long-term outcomes of allogeneic stem cell transplant in multiple myeloma","volume":"13","author":"Schmidt","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40487-022-00195-3","article-title":"Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma","volume":"10","author":"Claveau","year":"2022","journal-title":"Oncol. Ther."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/20\/6207\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:15:48Z","timestamp":1760112948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/20\/6207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":25,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["jcm13206207"],"URL":"https:\/\/doi.org\/10.3390\/jcm13206207","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]}}}